Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of STA-2 in Patients With Chronic Stable Angina

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Male or female aged \> 20;~2. Patients who had effort-induced angina which was relieved by rest or nitroglycerin, or who had catheterization-documented coronary artery disease or previous myocardial infarction ≥ 3 months before screening;~3. Patients who manifested positive ETT (exercise tolerance testing) (defined as ST-segment depression ≥ 1 mm compared with at rest, with or without limiting angina) at screening (Day -7);~4. Patients who manifested positive ETT (exercise tolerance testing) (defined as ST-segment depression ≥ 1 mm compared with at rest, with or without limiting angina) on the day of enrollment (Day 0). ETT performance between Day -7 and Day 0 were required not differ by \>20% in total exercise time;~5. Female patient who was in the post-menopausal stage or of childbearing potential who:~   * used adequate contraception since last menstruation and no plan for conception during the study;~  * was non-lactating;~  * had negative pregnancy test (urine) within 14 days prior to the study;~6. Able to provide written informed consent.~Exclusion criteria:~1. Patients with pre-excitation, conduction abnormalities, pacemaker rhythm, unstable angina or myocardial infarction within the preceding 3 months;~2. Patients with heart failure (New York Heart Association class III or IV), uncorrected valvular or congenital heart disease, patients who needed digoxin, isosorbide mononitrate, nitroglycerin sustained release preparation, theophylline, class I antiarrhythmic agents, digitalis, or monoamine oxidase inhibitors, as judged by the investigator;~3. Patients with any EKG abnormalities preventing the interpretation of ischemia (complete left bundle branch block);~4. Patients with Chronic Obstructive Pulmonary Disease (COPD) requiring bronchodilators;~5. Patients with hepatic failure (defined as aspartate transaminase (AST) and/or alanine transaminase (ALT) \> 3X the upper limit of normal values), and/or renal failure (defined as serum creatinine \> 3 mg/dL);~6. Patients with severe gastrointestinal illness as judged by the investigator;~7. Patient with any conditions that interfered the performance of exercise tolerance test as judged by investigator (e.g., knee/ankle arthropathy, Parkinsonism, stroke).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- STA-2 (Type: EXPERIMENTAL): STA-2 250 mg capsule, each containing 100 mg green tea polyphenols.~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsule, containing non-active ingredients.~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state.

Based on this trial design, predict the completion outcome and termination type (if applicable).